Orum Therapeutics, Inc. (475830.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	40.6M	23.6M	20.9B	135.4B	75.9M
Cost of Revenue	—	—	—	—	—
Gross Profit	40.6M	23.6M	20.9B	135.4B	75.9M
Operating Expenses
R&D Expense	48.4B	35.7B	17.0B	18.7B	33.2B
SG&A Expense	6.3B	5.9B	3.9B	13.1B	4.8B
General & Admin Expense	2.2B	2.4B	833.3M	771.0M	835.1M
Selling & Marketing Expense	4.1B	3.5B	3.1B	12.3B	4.0B
Other Expenses	10.9B	10.3B	8.3B	8.0B	5.7B
Total Operating Expenses	65.7B	51.8B	29.2B	39.8B	43.7B
Cost and Expenses	65.7B	51.8B	29.2B	39.8B	43.7B
Operating Income (EBIT)	(65.6B)	(51.8B)	(8.3B)	95.6B	(43.6B)
Non-Operating
Interest Income	2.3B	1.1B	3.2B	560.8M	671.0M
Interest Expense	1.9B	1.9B	1.8B	824.4M	75.4M
Net Interest Income	423.8M	(752.4M)	1.4B	(263.5M)	595.6M
Other Non-Op Income/Expense	82.0B	7.6B	3.0B	(27.7B)	(19.4B)
Non-Operating Income (excl Interest)	(83.8B)	(9.5B)	(4.8B)	26.9B	19.4B
EBT (Pre-Tax Income)	16.3B	(44.2B)	(5.3B)	67.9B	(63.1B)
Income Tax Expense	(2.2B)	(2.2B)	425.0M	(319.0M)	225.3M
Bottom Line
Net Income	18.5B	(42.0B)	(5.7B)	68.2B	(63.3B)
Earnings from Cont. Ops	18.5B	(42.0B)	(5.7B)	68.2B	(63.3B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	18.5B	(42.0B)	(5.7B)	68.2B	(63.3B)
Per Share
Basic EPS	₩863	(₩2,017)	(₩424)	₩14,830	(₩13,765)
Diluted EPS	₩862	(₩2,017)	(₩556)	₩5,646	(₩13,765)
Revenue Per Share	₩2	₩1	₩1,544	₩29,439	₩17
Shares
Basic Shares Outstanding	21.6M	20.8M	13.5M	4.6M	4.6M
Diluted Shares Outstanding	21.6M	20.8M	13.5M	12.1M	4.6M
Profitability Metrics
EBITDA	21.5B	(39.0B)	(653.2M)	71.3B	(60.9B)
D&A	3.3B	3.3B	2.9B	2.6B	2.1B
EBIT	18.2B	(42.3B)	(3.5B)	68.7B	(63.0B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026